MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2023.04.007

Медицинская библиотека · American heart journal · 2023

Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.

Spirito Alessandro, Koh Won-Joon, Sartori Samantha, Vogel Birgit, Feng Yihan, Baber Usman, Nicolas Johny, Snyder Clayton, Kamaleldin Karim, Pileggi Brunna, Rezvanizadeh Vahid, Sweeny Joseph, Sharma Samin K, Kini Annapoorna, Pocock Stuart J, Dangas George, Mehran Roxana

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The TWILIGHT trial (NCT02270242) demonstrated that in selected high-risk patients undergoing percutaneous coronary intervention (PCI) ticagrelor monotherapy significantly reduced bleeding complications without ischemic harm as compared to ticagrelor plus aspirin after 3-month of dual antiplatelet therapy. The aim of this analysis was to assess the applicability of the findings TWILIGHT trial to a real-world population.

METHODS

Patients undergoing PCI at a tertiary center between 2012 and 2019 and not meeting any TWILIGHT exclusion criterion (oral anticoagulation treatment, ST-segment elevation myocardial infarction [MI], cardiogenic shock, dialysis, prior stroke, or thrombocytopenia) were included. Patients were stratified into 2 groups based on whether they fulfilled the TWILIGHT inclusion criteria (high-risk) or not (low-risk). The primary outcome was all-cause death; the key secondary outcomes were MI and major bleeding at 1 year after PCI.

RESULTS

Out of 13,136 included patients, 11,018 (83%) were at high risk. At 1-year, these patients had an approximately 3 folds greater hazard of death (1.4% vs 0.4%, HR 3.63, 95% CI 1.70-7.77) and MI (1.8% vs 0.6%, HR 2.81, 95% CI 1.56-5.04) and a nearly 2 folds higher risk of major bleeding (3.3% vs 1.8%, HR 1.86, 95% CI 1.32-2.62) as compared to low-risk patients.

CONCLUSION

Among patients not meeting the TWILIGHT exclusion criteria from a large PCI registry, the high-risk inclusion criteria of the TWILIGHT trial were met by the majority of patients and were associated with an increased risk of mortality and MI and a moderately elevated risk of bleeding.

Для цитирования: Spirito Alessandro, Koh Won-Joon, Sartori Samantha, Vogel Birgit, Feng Yihan, Baber Usman, Nicolas Johny, Snyder Clayton, Kamaleldin Karim, Pileggi Brunna, Rezvanizadeh Vahid, Sweeny Joseph, Sharma Samin K, Kini Annapoorna, Pocock Stuart J, Dangas George, Mehran Roxana. Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.. American heart journal. 2023. DOI: 10.1016/j.ahj.2023.04.007.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.